Cargando…

Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of disease severity in subjects with Parkinson’s disease

BACKGROUND: Efforts to identify fluid biomarkers of Parkinson’s disease (PD) have intensified in the last decade. As the role of inflammation in PD pathophysiology becomes increasingly recognized, investigators aim to define inflammatory signatures to help elucidate underlying mechanisms of disease...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eidson, Lori N., Kannarkat, George T., Barnum, Christopher J., Chang, Jianjun, Chung, Jaegwon, Caspell-Garcia, Chelsea, Taylor, Peggy, Mollenhauer, Brit, Schlossmacher, Michael G., Ereshefsky, Larry, Yen, Mark, Kopil, Catherine, Frasier, Mark, Marek, Kenneth, Hertzberg, Vicki S., Tansey, Malú G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5563061/ https://www.ncbi.nlm.nih.gov/pubmed/28821274 http://dx.doi.org/10.1186/s12974-017-0935-1

Ejemplares similares

Critical Role of Regulator G-Protein Signaling 10 (RGS10) in Modulating Macrophage M1/M2 Activation
por: Lee, Jae-Kyung, et al.
Publicado: (2013)

RGS10 deficiency ameliorates the severity of disease in experimental autoimmune encephalomyelitis
por: Lee, Jae-Kyung, et al.
Publicado: (2016)

Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls
por: Mollenhauer, Brit, et al.
Publicado: (2017)

Longitudinal Analyses of Cerebrospinal Fluid α-Synuclein in Prodromal and Early Parkinson’s Disease
por: Mollenhauer, Brit, et al.
Publicado: (2019)

In vivo distribution of α-synuclein in multiple tissues and biofluids in Parkinson disease
por: Chahine, Lana M., et al.
Publicado: (2020)

Neuroimmunological processes in Parkinson's disease and their relation to α-synuclein: microglia as the referee between neuronal processes and peripheral immunity
por: Sanchez-Guajardo, Vanesa, et al.
Publicado: (2013)

A user's guide for α‐synuclein biomarker studies in biological fluids: Perianalytical considerations
por: Mollenhauer, Brit, et al.
Publicado: (2017)

Predicting Progression in Parkinson’s Disease Using Baseline and 1-Year Change Measures
por: Chahine, Lana M., et al.
Publicado: (2019)

α-Synuclein and Noradrenergic Modulation of Immune Cells in Parkinson’s Disease Pathogenesis
por: Butkovich, Laura M., et al.
Publicado: (2018)

Feasibility and Safety of Multicenter Tissue and Biofluid Sampling for α-Synuclein in Parkinson’s Disease: The Systemic Synuclein Sampling Study (S4)
por: Chahine, Lana M., et al.
Publicado: (2018)

Evaluation of the PREDIGT score’s performance in identifying newly diagnosed Parkinson’s patients without motor examination
por: Li, Juan, et al.
Publicado: (2022)

A First Tetraplex Assay for the Simultaneous Quantification of Total α-Synuclein, Tau, β-Amyloid(42) and DJ-1 in Human Cerebrospinal Fluid
por: Kruse, Niels, et al.
Publicado: (2016)

Relationships of gut microbiota, short-chain fatty acids, inflammation, and the gut barrier in Parkinson’s disease
por: Aho, Velma T. E., et al.
Publicado: (2021)

α-Synuclein in human cerebrospinal fluid is principally derived from neurons of the central nervous system
por: Mollenhauer, Brit, et al.
Publicado: (2012)

Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease
por: Oliveira, Luis M. A., et al.
Publicado: (2021)

Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson’s disease: the PPMI cohort
por: Simuni, Tanya, et al.
Publicado: (2018)

Targeting soluble tumor necrosis factor as a potential intervention to lower risk for late-onset Alzheimer’s disease associated with obesity, metabolic syndrome, and type 2 diabetes
por: De Sousa Rodrigues, Maria Elizabeth, et al.
Publicado: (2019)

Induction of α-synuclein aggregate formation by CSF exosomes from patients with Parkinson’s disease and dementia with Lewy bodies
por: Stuendl, Anne, et al.
Publicado: (2016)

Status of Current Biofluid Biomarkers in Parkinson's Disease
por: Mollenhauer, Brit
Publicado: (2023)

Baseline Cerebrospinal Fluid α-Synuclein in Parkinson’s Disease Is Associated with Disease Progression and Cognitive Decline
por: Emdina, Anna, et al.
Publicado: (2022)

Blood Contamination in CSF and Its Impact on Quantitative Analysis of Alpha-Synuclein
por: Barkovits, Katalin, et al.
Publicado: (2020)

Is LRRK2 the missing link between inflammatory bowel disease and Parkinson’s disease?
por: Herrick, Mary K., et al.
Publicado: (2021)

Psychological stress in adolescent and adult mice increases neuroinflammation and attenuates the response to LPS challenge
por: Barnum, Christopher J, et al.
Publicado: (2012)

Editorial: Glial-targeted therapeutics for CNS disease: getting there from here
por: Tansey, Malú Gámez, et al.
Publicado: (2023)

Interlaboratory validation of cerebrospinal fluid α-synuclein quantification in the diagnosis of sporadic Creutzfeldt-Jakob disease
por: Kruse, Niels, et al.
Publicado: (2018)

LRRK2 regulation of immune-pathways and inflammatory disease
por: Wallings, Rebecca L., et al.
Publicado: (2019)

Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort
por: Simuni, Tanya, et al.
Publicado: (2018)

Experimental colitis promotes sustained, sex-dependent, T-cell-associated neuroinflammation and parkinsonian neuropathology
por: Houser, Madelyn C., et al.
Publicado: (2021)

Validation of α-Synuclein as a CSF Biomarker for Sporadic Creutzfeldt-Jakob Disease
por: Llorens, Franc, et al.
Publicado: (2017)

Central and peripheral α‐synuclein in Parkinson disease detected by seed amplification assay
por: Chahine, Lana M., et al.
Publicado: (2023)

The gut-brain axis: is intestinal inflammation a silent driver of Parkinson’s disease pathogenesis?
por: Houser, Madelyn C., et al.
Publicado: (2017)

Neuroinflammation and tumor necrosis factor signaling in the pathophysiology of Alzheimer’s disease
por: McAlpine, Fiona E, et al.
Publicado: (2008)

Preanalytical Stability of CSF Total and Oligomeric Alpha-Synuclein
por: Abdi, Ilham Y., et al.
Publicado: (2021)

TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease
por: McCoy, Melissa K, et al.
Publicado: (2008)

Potential sources of interference with the highly sensitive detection and quantification of alpha‐synuclein seeds by qRT‐QuIC
por: Ruf, Viktoria C., et al.
Publicado: (2020)

Gut microbiome differences between amyotrophic lateral sclerosis patients and spouse controls
por: HERTZBERG, VICKI S., et al.
Publicado: (2022)

The GBA1 D409V mutation exacerbates synuclein pathology to differing extents in two alpha-synuclein models
por: Polinski, Nicole K., et al.
Publicado: (2022)

Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease
por: Irwin, David J., et al.
Publicado: (2020)

Peripheral and central immune system crosstalk in Alzheimer disease — a research prospectus
por: Bettcher, Brianne M., et al.
Publicado: (2021)

Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer’s disease core biomarkers in Lewy body disorders and Alzheimer’s dementia
por: Chiasserini, Davide, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_6hmaafr7vpvr8lonahre9eulo5